Alessandra MD - ESSA Pharma Chief Officer
| EPIX Stock | USD 1.79 0.02 1.10% |
Insider
Alessandra MD is Chief Officer of ESSA Pharma
| Age | 64 |
| Address | 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5 |
| Phone | 778 331 0962 |
| Web | https://www.essapharma.com |
ESSA Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1479) % which means that it has lost $0.1479 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1983) %, meaning that it created substantial loss on money invested by shareholders. ESSA Pharma's management efficiency ratios could be used to measure how well ESSA Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1.86 in 2024. Return On Capital Employed is likely to drop to -1.56 in 2024. At this time, ESSA Pharma's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 383.8 K in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 181.3 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Satyavrat CFA | Spero Therapeutics | 51 | |
| Alexandra MD | Avenue Therapeutics | 57 | |
| Ian Critchley | Spero Therapeutics | N/A | |
| Elaine JD | Summit Therapeutics PLC | 63 | |
| Jean Lechance | Altamira Therapeutics | N/A | |
| Ankur Dhingra | Summit Therapeutics PLC | 47 | |
| Covadonga Paeda | Altamira Therapeutics | N/A | |
| Angela MD | Spero Therapeutics | N/A | |
| Anne Heatherington | Summit Therapeutics PLC | N/A | |
| David Jin | Avenue Therapeutics | 34 | |
| FRS DBE | Summit Therapeutics PLC | 73 | |
| Michelle Avery | Summit Therapeutics PLC | N/A | |
| James Brady | Spero Therapeutics | N/A | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| Campbell Hair | Summit Therapeutics PLC | N/A | |
| Divya Chari | Summit Therapeutics PLC | 56 | |
| MBA MD | Spero Therapeutics | 43 | |
| Xiaoqin MD | Avenue Therapeutics | 49 | |
| Susannah Walpole | Spero Therapeutics | N/A | |
| DDS MBA | Summit Therapeutics PLC | 52 | |
| Marcel CPA | Altamira Therapeutics | 66 | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.15 |
ESSA Pharma Leadership Team
Elected by the shareholders, the ESSA Pharma's board of directors comprises two types of representatives: ESSA Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ESSA. The board's role is to monitor ESSA Pharma's management team and ensure that shareholders' interests are well served. ESSA Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ESSA Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Rudsinski, Executive | ||
| CMA CPA, Chief Officer | ||
| Terry Schuenemeyer, Executive | ||
| Neil Thapar, Executive | ||
| MS MBA, Executive COO | ||
| Nkengyal Barber, Executive | ||
| Alessandra MD, Chief Officer | ||
| Erica Osbourne, Executive | ||
| Chandtip Chandhasin, Executive | ||
| Loleta Harris, Executive | ||
| David MD, CEO and President and Director | ||
| Steve Pondell, Executive |
ESSA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ESSA Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (50.9 M) | ||||
| Shares Outstanding | 44.39 M | ||||
| Shares Owned By Insiders | 2.26 % | ||||
| Shares Owned By Institutions | 81.18 % | ||||
| Number Of Shares Shorted | 726.53 K | ||||
| Price To Earning | (1.12) X | ||||
| Price To Book | 0.62 X | ||||
| EBITDA | (26.46 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.